ME logo

23andMe Holding Co (ME) Company Overview

Profile

Full Name:

23andMe Holding Co.

Sector:

Healthcare

Industry:

Diagnostics & Research

Country:

United States

IPO:

November 23, 2020

Indexes:

Not included

Website:

http://www.23andme.com

Description:

23andMe Holding Co is a biotechnology company that offers genetic testing services. It provides customers with information about their ancestry, health traits, and genetic risks. Users send in a saliva sample, and the company analyzes their DNA to deliver personalized reports and insights about their genetic background.

Key Details

Price

$2.50

Market Cap

$67.07 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$219.64 M(-26.66% YoY)

Annual EPS

-$28.00(-102.90% YoY)

PE Ratio

-

Annual ROE

-147.75%

Annual Debt To Equity

0.00

Beta

1.23

Events Calendar

Earnings

Next earnings date:

May 23, 2025

Recent quarterly earnings:

Jan 28, 2025

Recent annual earnings:

May 23, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Oct 16, 2024

Analyst ratings

Recent major analysts updates

Apr 16, 24 Citigroup
Neutral
Aug 10, 23 Citigroup
Buy
May 26, 23 Credit Suisse
Outperform
May 26, 23 Citigroup
Neutral
Nov 29, 22 Berenberg
Buy
Nov 8, 22 Credit Suisse
Outperform
Sep 22, 22 Cowen & Co.
Outperform
Aug 10, 22 Citigroup
Neutral
May 27, 22 Credit Suisse
Outperform
May 27, 22 Citigroup
Neutral

Screeners with ME included

Growing Shares Outstanding
US stocks
Stocks with high beta
Biggest stock losers today
Stocks below SMA 200
Healthcare sector
All stocks
Stocks above analysts price target
Stocks recommended to sell
Small cap stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$2.50
ME price is $2.50

Price All-time High

$353.00
ME price is currently -99.29% below its historical high of $353.00

Price Analysts Target

$2.08
ME price is currently +20.19% higher than the consensus analysts' forecast

Price Most Recent Change

-15.25%
ME price was down -15.25% on Feb 22, 2025

Price YTD Change

-21.63%
ME price is down -21.63% since January 1st

Price 3-Year Change

-97.18%
ME price is down -97.18% over the past 3 years

Market cap

Market Cap

$67.07 M
ME market capitalization is $67.07 million

Market Cap 3-Year Change

-96.62%
ME market capitalization is down -96.62% over the past 3 years

Market Cap All-time High

$5.80 B
ME market capitalization is currently -98.84% below its historical high of $5.80 billion

Market Cap Sector Rank

39.02%
ME market capitalization is higher than 39.02% of companies in Healthcare sector

Technical

Beta

1.23
ME beta is 1.23

200-day SMA

$6.14
ME price is currently -59.31% below its 200-day simple moving average

14-day RSI

32.49
ME 14-day relative strength index is 32.49

30-day Relative Volume

1.58
ME 30-day relative volume is 1.58

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$219.64 M
ME annual revenue is $219.64 million

Annual Revenue Analysts Estimate

$260.32 M
ME annual revenue is currently -15.63% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

-26.66%
ME annual revenue is down -26.66% year-on-year

Annual Revenue Sector Rank

66.07%
ME annual revenue is higher than 66.07% of companies in Healthcare sector

Profit

Annual Gross Profit

$99.38 M
ME annual gross profit is $99.38 million

Annual Gross Margin

45.25%
ME annual gross profit margin is 45.25%

Annual Operating Profit

-$321.36 M
ME annual operating income is -$321.36 million

Annual Operating Margin

-146.31%
ME annual operating profit margin is -146.31%

Annual Net Income

-$666.70 M
ME annual net profit is -$666.70 million

Annual Net Margin

-303.55%
ME annual net profit margin is -303.55%

EPS

Annual EPS

-$28.00
ME annual earnings per share is -$28.00

Annual EPS Analysts Estimate

-
ME annual earnings per share consensus analysts' forecast is unknown

Annual EPS 1-Year Change

-102.9%
ME annual earnings per share is down -102.9% year-on-year

Annual EPS Sector Rank

8.35%
ME annual earnings per share is higher than 8.35% of companies in Healthcare sector

ROA & ROE

Annual ROA

-99.67%
ME annual return on assets is -99.67%

Annual ROE

-147.75%
ME annual return on equity is -147.75%

EBIT & EBITDA

Annual EBIT

-$321.36 M
ME annual earnings before interest & taxes is -$321.36 million

Annual EBITDA

-$291.87 M
ME annual EBITDA is -$291.87 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
ME price to earnings ratio value is unknown

PE Ratio Sector Rank

-
ME price to earnings ratio is unknown

PB Ratio

PB Ratio

1.07
ME price to book ratio is 1.07

PB Ratio Sector Rank

43.24%
ME price to book ratio is higher than 43.24% of companies in Healthcare sector

PS Ratio

PS Ratio

0.32
ME price to sales ratio is 0.32

PS Ratio Sector Rank

9.25%
ME price to sales ratio is higher than 9.25% of companies in Healthcare sector

Enterprise value

Enterprise Value

$48.26 M
ME enterprise value is $48.26 million

Enterprise Value Sector Rank

39.95%
ME enterprise value is higher than 39.95% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.26
ME EV/EBITDA is -0.26

EV/EBITDA Sector Rank

61.92%
ME EV/EBITDA is higher than 61.92% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

2.01
ME annual current ratio is 2.01

Annual Quick Ratio

1.91
ME annual quick ratio is 1.91

Leverage

Annual Debt To Equity

0.00
ME annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-
ME annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

4
ME piotroski f-score is 4

Altman Z-Score

-9.24
ME altman z-score is -9.24

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$395.17 M
ME annual total assets is $395.17 million

Annual Non Current Assets

$139.86 M
ME annual long term assets is $139.86 million

Annual Current Assets

$255.31 M
ME annual total current assets is $255.31 million

Annual Cash & Cash Equivalents

$216.49 M
ME annual cash & cash equivalents is $216.49 million

Equity

Annual Book Value

$188.52 M
ME annual book value is $188.52 million

Annual Working Capital

$127.98 M
ME annual working capital is $127.98 million

Liabilities

Annual Total Liabilities

$206.65 M
ME annual total liabilities is $206.65 million

Annual Total Long Term Liabilities

$79.32 M
ME annual total long term liabilities is $79.32 million

Annual Current Liabilities

$127.33 M
ME annual total current liabilities is $127.33 million

Annual Accounts Payable

$11.57 M
ME annual accounts payable is $11.57 million

Debt

Annual Total Debt

$76.52 M
ME annual total debt is $76.52 million

Annual Total Debt 1-Year Change

-10.3%
ME annual total debt is down -10.3% year-on-year

Annual Long Term Debt

$67.84 M
ME annual long term debt is $67.84 million

Annual Short Term Debt

$8.67 M
ME annual short term debt is $8.67 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$540.99 M
ME annual total expenses is $540.99 million

Annual Operating Expenses

$420.73 M
ME annual total operating expenses is $420.73 million

Annual Cost Of Goods Sold

$120.26 M
ME annual cost of goods sold is $120.26 million

Annual SGA

$215.37 M
ME annual SGA is $215.37 million

Annual D&A

$29.48 M
ME annual depreciation & amortization is $29.48 million

Annual Interest Expense

-
ME annual interest expense value is unknown

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$164.32 M
ME annual cash flow from operations is -$164.32 million

Annual CFO 1-Year Change

+0.65%
ME annual cash flow from operations is up +0.65% year-on-year

Annual CFI

-$9.63 M
ME annual cash flow from investing activities is -$9.63 million

Annual CFI 1-Year Change

+14.85%
ME annual cash flow from investing activities is up +14.85% year-on-year

Annual CFF

$3.58 M
ME annual cash flow from financing activities is $3.58 million

Annual CFF 1-Year Change

-63.34%
ME annual cash flow from financing activities is down -63.34% year-on-year

Free CashFlow

Annual FCF

-$173.97 M
ME annual free cash flow is -$173.97 million

Annual FCF 1-Year Change

+1.54%
ME annual free cash flow is up +1.54% year-on-year

CAPEX

Annual CAPEX

$9.66 M
ME annual capital expenditures is $9.66 million

Annual CAPEX 1-Year Change

-14.62%
ME annual capital expenditures is down -14.62% year-on-year

Institutional Ownership

Similar stocks

IKNA logo
Ikena Oncology (IKNA)
Artiva Biotherapeutics (ARTV)
XGN logo
Exagen (XGN)
FGEN logo
FibroGen (FGEN)
MRSN logo
Mersana Therapeutics (MRSN)
STTK logo
Shattuck Labs (STTK)
AVTE logo
Aerovate Therapeutics (AVTE)
VANI logo
Vivani Medical (VANI)
AADI logo
Aadi Bioscience (AADI)

FAQ

  • What is the ticker symbol for 23andMe Holding Co?
  • Does 23andMe Holding Co pay dividends?
  • What sector is 23andMe Holding Co in?
  • What industry is 23andMe Holding Co in?
  • What country is 23andMe Holding Co based in?
  • When did 23andMe Holding Co go public?
  • Is 23andMe Holding Co in the S&P 500?
  • Is 23andMe Holding Co in the NASDAQ 100?
  • Is 23andMe Holding Co in the Dow Jones?
  • When was 23andMe Holding Co's last earnings report?
  • When does 23andMe Holding Co report earnings?
  • Should I buy 23andMe Holding Co stock now?

What is the ticker symbol for 23andMe Holding Co?

The ticker symbol for 23andMe Holding Co is NASDAQ:ME

Does 23andMe Holding Co pay dividends?

No, 23andMe Holding Co does not pay dividends

What sector is 23andMe Holding Co in?

23andMe Holding Co is in the Healthcare sector

What industry is 23andMe Holding Co in?

23andMe Holding Co is in the Diagnostics & Research industry

What country is 23andMe Holding Co based in?

23andMe Holding Co is headquartered in United States

When did 23andMe Holding Co go public?

23andMe Holding Co's initial public offering (IPO) was on November 23, 2020

Is 23andMe Holding Co in the S&P 500?

No, 23andMe Holding Co is not included in the S&P 500 index

Is 23andMe Holding Co in the NASDAQ 100?

No, 23andMe Holding Co is not included in the NASDAQ 100 index

Is 23andMe Holding Co in the Dow Jones?

No, 23andMe Holding Co is not included in the Dow Jones index

When was 23andMe Holding Co's last earnings report?

23andMe Holding Co's most recent earnings report was on Jan 28, 2025

When does 23andMe Holding Co report earnings?

The next expected earnings date for 23andMe Holding Co is May 23, 2025

Should I buy 23andMe Holding Co stock now?

As of today, analysts generally recommend a 'Sell' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions